These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33475845)

  • 1. The prevalence of intestinal dysbiosis in patients referred for antireflux surgery.
    Haworth JJ; Boyle N; Vales A; Hobson AR
    Surg Endosc; 2021 Dec; 35(12):7112-7119. PubMed ID: 33475845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
    de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
    World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term PPI treatment on producing bowel symptoms and SIBO.
    Compare D; Pica L; Rocco A; De Giorgi F; Cuomo R; Sarnelli G; Romano M; Nardone G
    Eur J Clin Invest; 2011 Apr; 41(4):380-6. PubMed ID: 21128930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.
    Lombardo L; Foti M; Ruggia O; Chiecchio A
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):504-8. PubMed ID: 20060064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care.
    DE Bastiani R; Lopetuso LR; DE Bastiani M; Bacchin P; Benedetto E; Boscariolo L; Caneve R; Chesani F; Chiumeo F; Civic Z; Dainese A; DE Polo M; Disclafani G; Grattagliano I; Mana O; Mancuso M; Mastronuzzi T; Pati A; Pirrotta E; Salandini M; Sanna G; Scoglio R; Severino P; Tosetti C; Turnava L; Zamparella M; Elisei W; Gasbarrini A; Tursi A
    Minerva Gastroenterol (Torino); 2023 Dec; 69(4):523-528. PubMed ID: 36943203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors
    Revaiah PC; Kochhar R; Rana SV; Berry N; Ashat M; Dhaka N; Rami Reddy Y; Sinha SK
    JGH Open; 2018 Apr; 2(2):47-53. PubMed ID: 30483563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel.
    Jobe BA; Richter JE; Hoppo T; Peters JH; Bell R; Dengler WC; DeVault K; Fass R; Gyawali CP; Kahrilas PJ; Lacy BE; Pandolfino JE; Patti MG; Swanstrom LL; Kurian AA; Vela MF; Vaezi M; DeMeester TR
    J Am Coll Surg; 2013 Oct; 217(4):586-97. PubMed ID: 23973101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between chronic use of proton pump inhibitors and small- intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests.
    Fujiwara Y; Watanabe T; Muraki M; Yamagami H; Tanigawa T; Shiba M; Tominaga K; Arakawa T
    Hepatogastroenterology; 2015; 62(138):268-72. PubMed ID: 25916046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial High-Resolution Impedance Manometry Identifies Mechanisms of Nonresponse to Proton Pump Inhibitors.
    Yadlapati R; Tye M; Roman S; Kahrilas PJ; Ritter K; Pandolfino JE
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):211-218.e1. PubMed ID: 28911949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics.
    Kiecka A; Szczepanik M
    Pharmacol Rep; 2023 Aug; 75(4):791-804. PubMed ID: 37142877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the patient with incomplete response to PPI therapy.
    Kahrilas PJ; Boeckxstaens G; Smout AJ
    Best Pract Res Clin Gastroenterol; 2013 Jun; 27(3):401-14. PubMed ID: 23998978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belching: dyspepsia or gastroesophageal reflux disease?
    Lin M; Triadafilopoulos G
    Am J Gastroenterol; 2003 Oct; 98(10):2139-45. PubMed ID: 14572558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study examining the impact of multichannel intraluminal impedance on antireflux surgery.
    Gruebel C; Linke G; Tutuian R; Hebbard G; Zerz A; Meyenberger C; Borovicka J
    Surg Endosc; 2008 May; 22(5):1241-7. PubMed ID: 17943361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Future Approaches for Diagnosing Small Intestinal Dysbiosis in Patients With Symptoms of Functional Dyspepsia.
    Shah A; Talley NJ; Holtmann G
    Front Neurosci; 2022; 16():830356. PubMed ID: 35600619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of laparoscopic antireflux surgery for gastroesophageal reflux disease (GERD)-related airway disorder.
    Kaufman JA; Houghland JE; Quiroga E; Cahill M; Pellegrini CA; Oelschlager BK
    Surg Endosc; 2006 Dec; 20(12):1824-30. PubMed ID: 17063301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impedance-pH monitoring on medications does not reliably confirm the presence of gastroesophageal reflux disease in patients referred for antireflux surgery.
    Ward MA; Dunst CM; Teitelbaum EN; Halpin VJ; Reavis KM; Swanström LL; DeMeester SR
    Surg Endosc; 2018 Feb; 32(2):889-894. PubMed ID: 28779252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico.
    Schmulson MJ; Frati-Munari AC
    Rev Gastroenterol Mex (Engl Ed); 2019; 84(1):44-51. PubMed ID: 29678362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
    Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.